Corpus Intelligence IC Memo — KFH - FRESNO 2026-04-26 04:04 UTC
IC Memo — KFH - FRESNO
Investment Committee Memorandum | CA | 169 beds | Grade C | EBITDA uplift $33.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

KFH - FRESNO

CCN 050710 | FRESNO, CA | 169 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

KFH - FRESNO is a 169-bed suburban community hospital in FRESNO, CA with $456.9M in net patient revenue and a 13.0% operating margin. The hospital serves a payer mix of 3.1% Medicare, 0.8% Medicaid, and 96.0% commercial.

Thesis: Turnaround. Our ML models identify $33.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 13.0% to 20.3% (+736bps).

Net Revenue HCRIS$456.9M
Current EBITDA COMPUTED$59.2M
Operating Margin COMPUTED13.0%
Occupancy HCRIS55.3%
Revenue / Bed COMPUTED$2.7M
Net-to-Gross HCRIS26.9%
Distress Probability ML42.7%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
207
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 13.0% places it above the state median. Among 207 size-comparable peers (84-338 beds), the median margin is -4.6%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (84-338), prioritizing same-state peers. 207 hospitals in the comp set.

HospitalStateBedsRevenueMargin
KFH - FRESNO (Target)CA169$456.9M13.0%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
CHILDRENS HOSPITAL OF ORANGE CCA334$1.31B0.7%
KECK HOSPITAL OF USCCA301$1.11B-20.8%
SUTTER ROSEVILLE MEDICAL CENTECA318$1.07B12.1%
CALIFORNIA PACIFIC MEDICAL CENCA274$987.8M-18.5%
ZUCKERBERG SAN FRANCISCO GENERCA284$889.5M-41.7%
SANTA MONICA UCLA MEDICAL CENTCA281$835.9M2.8%
ENLOE MEDICAL CENTERCA258$834.4M-0.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $33.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$9.6M+210bp18mo
Cost to Collect4.5%2.5%$9.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$9.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$5.6M+122bp9mo
Clean Claim Rate88.0%96.0%$292K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$9.6M
Cost to Collect
$9.1M
Denial Rate Reduction
$9.0M
A/R Days Reduction
$5.6M
Clean Claim Rate
$292K
Total EBITDA Uplift$33.6M
Current EBITDA$59.2M
+ RCM Uplift+$33.6M
Pro Forma EBITDA$92.8M
Current Margin13.0%
Pro Forma Margin20.3%
WC Released (1x)$17.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$91.1M$726.8M7.98x51.5%
Base (11x exit)10.0x11.0x$91.1M$829.0M9.10x55.5%
Bull Case9.0x11.0x$82.0M$969.6M11.83x63.9%
Bull (12x exit)9.0x12.0x$82.0M$1.08B13.20x67.5%
Bear Case11.0x10.0x$100.2M$529.0M5.28x39.5%
Bear (11x exit)11.0x11.0x$100.2M$614.4M6.13x43.7%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 207 hospitals with 84-338 beds
  • Same-state prioritization (n=208)
  • Comp margins: P25=-17.6% / P50=-4.6% / P75=3.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.